Effect of fluticasone 250 μg/salmeterol 50 μg and montelukast on exhaled nitric oxide in asthmatic patients

Canadian Respiratory Journal

Volumn 15, Issue 4, 2008, Pages 193-198

  Gelb, Arthur F ^a,b   Taylor, Colleen Flynn ^b   Shinar, Chris M ^c   Gutierrez, Carlos A ^d   Zamel, Noe ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Orange Coast Memorial Medical Center ^*

^c Orange Coast Memorial Medical Center   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Asthma; Exhaled nitric oxide; Montelukast; Salmeterol fluticasone

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NITRIC OXIDE; SALBUTAMOL; SALMETEROL;

ADD ON THERAPY; ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; EXHALATION; EXPIRED AIR; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG ALVEOLUS; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; METERED DOSE INHALER; MONOTHERAPY; NON INVASIVE MEASUREMENT; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SPIROMETRY; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 48449100901     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/415391     Document Type: Article

References (55)

1. Gelb AF, Flynn Taylor C, Shinar CM, Gutierrez C, Zamel N. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest 2006;129:1492-9.
2. Kharitonov SA, Gonio F, Kelly C, Meah S, Barnes PJ. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J 2003;21:433-8.
3. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled tower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912-30.
4. Silkoff PE, Lent AM, Busacker AA, et al. Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol 2005;116:1249-55.
5. Lim S, Jatakanon A, Meah S, Oates T, Chung KF, Barnes PJ. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma. Thorax 2000;55:184-8.
6. Hamid Q, Springall DR, Riveros-Moreno V, et al. Induction of nitric oxide synthase in asthma. Lancet 1993;342:1510-3.
7. Gelb AF, Flynn Taylor C, Nussbaum E, et al. Alveolar and airway sites of nitric oxide inflammation in treated asthma. Am J Respir Crit Care Med 2004;170:737-41.
8. Lehtimäki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E. Inhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma. Eur Respir J 2001;18:635-9.
9. Berry M, Hargadon B, Morgan A, et al. Alveolar nitric oxide in adults with asthma: Evidence of distal lung inflammation in refractory asthma. Eur Respir J 2005;25:986-91.
10. Jones SL, Kittelson J, Cowan JO, et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 2001;164:738-43.
11. Leuppi JD, Salome CM, Jenkins CR, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001;163:406-12.
12. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000;161:64-72.
13. Pijnenburg MW, Hofhuis W, Hop WC, De Jongste JC. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax 2005;60:215-8.
14. Stirling RG, Kharitonov SA, Campbell D, et al. Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids. Asthma and Allergy Group. Thorax 1998;53:1030-4.
15. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial. Lancet 2002;360:1715-21.
16. Covar RA, Szefler SJ, Martin RJ, et al. Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma. J Pediatr 2003;142:469-75.
17. van Rensen EL, Straathof KC, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999;54:403-8.
18. Smith AD, Cowan JO, Brassett KF, Herbison GF, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352:2163-73.
19. Green RH, Brightling CE, McKenna S, et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. Eur Respir J 2006;27:1144-51.
20. Lee MY, Lai YS, Yang KD, Chen CJ, Hung CH. Effects of montelukast on symptoms and eNO in children with mild to moderate asthma. Pediatr Int 2005;47:622-6.
21. Straub DA, Minocchieri S, Moeller A, Hamacher J, Wildhaber JH. The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old. Chest 2005;127:509-14.
22. Bratton DL, Lanz MJ, Miyazawa N, White CW, Silkoff PE. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: A preliminary study. Pediatr Pulmonol 1999;28:402-7.
23. Sandrini A, Ferreira I, Gutierrez C, Jardim JR, Zamel N, Chapman KR. Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma. Chest 2003;124:1334-40.
24. Lee DK, Jackson CM, Haggart K, Lipworth BJ. Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients. Chest 2004;125:1372-7.
25. Biernacki WA, Kharitonov SA, Biernacka HM, Barnes PJ. Effect of montelukast on exhaled leukotrienes and quality of life in asthmatic patients. Chest 2005;128:1958-63.
26. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 2003;167:1232-8.
27. Ghiro L, Zanconato S, Rampon O, Piovan V, Pasquale MF, Baraldi E. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. Eur Respir J 2002;20:630-4.
28. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Resp Crit Care Med 1999;160:1862-8.
29. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005;115:233-42.
30. Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006;117:45-52.
31. Peroni D, Bodini A, Miraglia Del Giudice M, et al. Effect of budesonide and montelukast in asthmatic children exposed to relevant allergens. Allergy 2005;60:206-21.
32. Kanniess F, Richter K, Böhme S, Jörres RA, Magnussen H. Montelukast versus fluticasone: Effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J 2002;20:853-8.
33. Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol 1998;85:653-66.
34. National Asthmatic Education and Prevention Program. Clinical Practice Guidelines. Expert Panel Report 2. Guidelines for the Diagnosis and Management of Asthma. (Version current at May 15, 2008).
35. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, National Institutes of Health, National Heart, Lung, and Blood Institute, revised 2002. (Version current at May 15, 2008).
36. Gelb AF, Hogg JC, Müller NL, et al. Contribution of emphysema and small airways in COPD. Chest 1996;109:353-9.
37. Tsoukias NM, Shin HW, Wilson AF, George SC. A single-breath technique with variable flow rate to characterize nitric oxide exchange dynamics in the lungs. J Appl Physiol 2001;91:477-87.
38. George SC, Hogman M, Permutt S, Silkoff PE. Modeling pulmonary nitric oxide exchange. J Appl Physiol 2004;96:831-9.
39. Silkoff PE, McClean PA, Slutsky AS, et al. Marked flow, dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. Am J Resp Crit Care Med 1997;155:260-7.
40. Gelb AF, Licuanan J, Shinar CM, Zamel N. Unsuspected loss of lung elastic recoil in chronic persistent asthma. Chest 2002;121:715-21.
41. Gelb AF, Zamel N. Unsuspected pseudophysiologic emphysema in chronic persistent asthma. Am J Respir Crit Care Med 2000;162:1778-82.
42. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999;14:32-8.
43. Gelb AF, Flynn Taylor C, Epstein JD, Shinar CM, Gutierrez C, Zamel N. Effect of fluticasone/salmeterol and montelukast on total exhaled, bronchial, and alveolar nitric oxide in asthmatics. Chest 2004;126:813S-4S. (Abst)
44. Kharitonov SA, Donnelly LE, Montuschi P, Corradi M, Collins JV, Barnes PJ. Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax 2002;57:889-96.
45. Overbeek SE, O'Sullivan S, Leman K, Mulder PG, Hoogsteden HC, Prins JB. Effect of montelukast compared with inhaled fluticasone on airway inflammation. Clin Exp Allergy 2004;34:1388-94.
46. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: One year, double blind, randomised, comparative trial. BMJ 2003;327:891-7.
47. Ilowite J, Webb R, Friedman B, et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: A randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004;92:641-8.
48. van Veen IH, Sterk PJ, Schur R, Gauw SA, Rabe KF, Bel EH. Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. Eur Respir J 2006;27:951-6.
49. Mahut B, Delacourt C, Zerah-Lancner F, De Blic J, Harf A, Delclaux C. Increase in alveolar nitric oxide in the presence of symptoms in childhood asthma. Chest 2004;125:1012-8.
50. Högman M, Holmkvist T, Wegener T, et al. EExtended NO analysis applied to patients with COPD, allergic asthma and allergic rhinitis. Respir Med 2002;96:24-30.
51. Shin HW, Rose-Gottron CM, Cooper DM, Newcomb RL, George SC. Airway diffusing capacity of nitric oxide and steroid therapy in asthma. J Appl Physiol 2004;96:65-75.
52. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: Role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004;113:101-8.
53. Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996;154:1505-10.
54. Mauad T, Xavier AC, Saldiva PH, Dollmikoff M, Elastosis and fragmentation of fibers of the elastic system in fatal asthma. Am J Respir Crit Care Med 1999;160:968-75.
55. Mauad T, Silva LF, Santos MA, et al. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. Am J Respir Crit Care Med 2004;170:857-62.